Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer

Jazz Pharmaceuticals plc JAZZ and Zymeworks Inc ZYME announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial of zanidatamab plus chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
The preliminary results showed that the median OS had not yet been reached, with a median duration of study follow-up of 26.5 months.
The 18-month overall survival rate was 84%.
Related: Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks.
Treatment with zanidatamab resulted in a confirmed objective response rate of 79% and a disease control rate of 92%, with three patients achieving complete response among 38 response-evaluable patients.
The median duration of response was 20.4 months, with a median progression-free survival of 12.5 months, with 17 patients having an ongoing response at the time of data cutoff.
The regimen was manageable, tolerable, and consistent with the observed safety profiles reported for other standard combination regimens for patients with HER2-positive GEA.
Zymeworks continues to enroll patients in the Phase 3 HERIZON-GEA-01 trial of zanidatamab plus chemotherapy plus or minus tislelizumab as a first-line treatment for HER2-expressing mGEA.
Price Action: JAZZ shares are up 0.84% at $156.18, and ZYME shares are down 4.50% at $9.55 on the last check Thursday.